A phase I study of Lapatinib (GW572016) and topotecan in patients with solid tumors.

被引：0
|
作者：
Erlichman, C
Adjei, AA
Joy, ME
Rubin, SD
Friedman, RA
Ames, MM
Reid, JM
Molina, JR
机构：
[1] Mayo Clin, Rochester, MN USA
[2] GlaxoSmithKline Oncol, Res Triangle Pk, NC USA
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：8994S / 8994S
页数：1
相关论文
共 50 条
  • [41] Final results of a phase I study of lapatinib (LAP) and cetuximab (CET) in patients with CET-sensitive solid tumors.
    Deeken, John F.
    Wang, Hongkun
    Marshall, John
    Subramaniam, Deepa Suresh
    Hwang, Jimmy J.
    He, Aiwu Ruth
    Ramos, Corinne
    Hardesty, Rosemarie A.
    Steadman, Kenneth
    Weiner, Louis M.
    Pishvaian, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Interim results of a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with FISH-amplified advanced or metastatic breast cancer
    Stein, S. H.
    Gomez, H. L.
    Chavez, M. A.
    Doval, D. C.
    Chow, L. W.
    Newstat, B.
    Berger, M. S.
    Sledge, G. W.
    EJC SUPPLEMENTS, 2005, 3 (02): : 78 - 78
  • [43] Characterizing response to lapatinib (GW572016) in non-Her2 amplified tumor-derived cell lines
    Greshock, Joel
    Cornwell, William D.
    Degenhardt, Yan Y.
    Bachman, Kurtis E.
    Moy, Christopher
    Rusnak, David W.
    Martin, Anne-Marie
    Gilmer, Tona M.
    Cheng, Jie
    Lee, Kwan
    Zaks, Tal Z.
    Weber, Barbara L.
    Wooster, Richard F.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3573S - 3573S
  • [44] A phase I study of ixabepilone combined with dasatinib in patients with solid tumors.
    Kaiser, C. C.
    Perry, D. J.
    Zimmer, A. S.
    Patterson, J. W.
    Swain, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] A phase I study of intravenous artesunate (IV AS) in patients with solid tumors.
    Deeken, John F.
    Wang, Hongkun
    Smaglo, Brandon George
    Hwang, Jimmy J.
    He, Aiwu Ruth
    Weiner, Louis M.
    Marshall, John
    Giaccone, Giuseppe
    Liu, Stephen V.
    Luecht, Jim
    Urso, Christina
    Spiegel, Jay Y.
    Cheema, Amrita
    Pishvaian, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors.
    Tolaney, Sara M.
    Hilton, John Frederick
    Cleary, James M.
    Gandhi, Leena
    Kwak, Eunice Lee
    Clark, Jeffrey W.
    Wolanski, Andrew
    Bell, Tracy Demeo
    Rodig, Scott J.
    Chiao, Judy H.
    Blake, David
    Shapiro, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] A phase I QTc study of tivozanib in patients with advanced solid tumors.
    Chadha, Manpreet Kaur
    Infante, Jeffrey R.
    Cotreau, Monette M.
    Jacobson, Lindsey
    Strahs, Andrew Louis
    Slichenmyer, William
    Vargo, Dennis
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [48] A phase I study of topotecan and gemcitabine in advanced solid tumors
    Derek S. Serna
    Tanios Bekaii-Saab
    Eric H. Kraut
    Investigational New Drugs, 2011, 29 : 1390 - 1394
  • [49] An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer.
    Fields, ALA
    Rinaldi, DA
    Henderson, CA
    Germond, CJ
    Chu, L
    Brill, KJ
    Leopold, LH
    Berger, MS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 266S - 266S
  • [50] Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
    Iqbal, S.
    Goldman, B.
    Fenoglio-Preiser, C. M.
    Lenz, H. J.
    Zhang, W.
    Danenberg, K. D.
    Shibata, S. I.
    Blanke, C. D.
    ANNALS OF ONCOLOGY, 2011, 22 (12) : 2610 - 2615
12345